Table 3.
Adjusted mortality risk for colistin versus new agents among propensity score-matched sample, without accounting for joint effects of treatment and AKI
| Final stepwise model: treatment and AKI forced into modela | OR estimate | Lower 95% CI | Upper 95% CI | p value |
|---|---|---|---|---|
| Ventilated at ANY point | 13.80 | 5.02 | 37.88 | < 0.0001 |
| Age | 1.03 | 1.01 | 1.06 | 0.006 |
| Mild liver disease | 2.65 | 0.96 | 7.33 | 0.060 |
| Malignancy | 12.53 | 5.04 | 31.15 | < 0.0001 |
| Treatment colistin vs. new agents | 1.36 | 0.74 | 2.51 | 0.318 |
| AKI yes vs. no | 3.81 | 2.00 | 7.27 | < 0.0001 |
AKI acute kidney injury
aStepwise algorithm eliminating covariates with p value > 0.15 except for treatment and AKI